Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danbi Lee

Showing results (151-160 of 181) with videos related to

Pageof 19
Sort By:
Oncotarget|August 6, 2016
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinomaYeonjung Ha, Danbi Lee, Ju Hyun Shim, et al.
Digestive Diseases and Sciences|October 14, 2017
Correction to: Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular CarcinomaJong Kwan Kim, Hyung-Don Kim, Mi-Jung Jun, et al.
Cancer Research and Treatment|May 22, 2025
Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score-Weighted AnalysisSumin Lee, Jinhong Jung, Jonggi Choi, et al.
Cancer|June 28, 2012
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinomaJoo Ho Lee, Young-Hwa Chung, Jeong A Kim, et al.
Journal of Korean Medical Science|February 3, 2011
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?Yoon Kyung Park, Kang Mo Kim, Young-Joo Lee, et al.
Liver Cancer|May 12, 2021
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective StudyChanghoon Yoo, Jwa Hoon Kim, Min-Hee Ryu, et al.
BMC Cancer|February 17, 2022
Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patientsSumin Lee, Jinhong Jung, Jin-Hong Park, et al.
Experimental & Molecular Medicine|April 28, 2018
Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolutionHye Shin Lee, Jinhyeok Choi, Taekwon Son, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 28, 2013
Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patternsWonhyeong Park, Young-Hwa Chung, Jeong A Kim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinomaEo Jin Kim, Changhoon Yoo, Hyo Jeong Kang, et al.
Pageof 19

Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
Oncotarget|August 6, 2016
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinomaYeonjung Ha, Danbi Lee, Ju Hyun Shim, et al.
Digestive Diseases and Sciences|October 14, 2017
Correction to: Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular CarcinomaJong Kwan Kim, Hyung-Don Kim, Mi-Jung Jun, et al.
Cancer Research and Treatment|May 22, 2025
Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score-Weighted AnalysisSumin Lee, Jinhong Jung, Jonggi Choi, et al.
Cancer|June 28, 2012
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinomaJoo Ho Lee, Young-Hwa Chung, Jeong A Kim, et al.
Journal of Korean Medical Science|February 3, 2011
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?Yoon Kyung Park, Kang Mo Kim, Young-Joo Lee, et al.
Liver Cancer|May 12, 2021
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective StudyChanghoon Yoo, Jwa Hoon Kim, Min-Hee Ryu, et al.
BMC Cancer|February 17, 2022
Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patientsSumin Lee, Jinhong Jung, Jin-Hong Park, et al.
Experimental & Molecular Medicine|April 28, 2018
Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolutionHye Shin Lee, Jinhyeok Choi, Taekwon Son, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 28, 2013
Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patternsWonhyeong Park, Young-Hwa Chung, Jeong A Kim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinomaEo Jin Kim, Changhoon Yoo, Hyo Jeong Kang, et al.
Pageof 19